Ally Bridge Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ally Bridge Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-105,558	Closed	-$10.8M	–	25
2023 Q2	$10.8M	Buy	+105,558	New	+$9.99M	13.04%	1

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ally Bridge Group's RETA Position: Q3 2023 in Review

Ally Bridge Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 105,558 shares — an estimated $10.8M sold.

Ally Bridge Group first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $10.8M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Ally Bridge Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Ally Bridge Group sold 105,558 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $10.8M.
Ally Bridge Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Ally Bridge Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10.8M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Ally Bridge Group's 13F filing for Q3 2023, filed 14 Nov 2023.